Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Estranes”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1989

11 beta-nitrate estrane analogues: potent estrogens.

Various estrane derivatives 1 reacted with cerium ammonium nitrate (CAN) selectively and efficiently to provide 9 alpha,11 beta-defunctionalized derivatives 2, which were subsequently deoxygenated at C-9 with triethylsilane/boron trifluoride etherate to the desired target 11 beta-nitratoestranes 3a, 3b, and 5. When examined for estrogenic and postcoital antifertility activity, 11 beta-nitrates 2c, 2d, and 3b most notably displayed more potent oral activity than did ethynylestradiol.

Animals↗
PubMed1983

HPLC-RIA of a metabolite of norethindrone in human plasma, 17 alpha-ethinyl-5 beta-estrane-3 alpha, 17 beta-diol, following conjugate hydrolysis.

An HPLC-RIA method for the assay of a reduced metabolite of norethindrone, 17 alpha-ethinyl-5 beta-estrane-3 alpha, 17 beta-diol, is described. Conjugated metabolites were extracted from human plasma and subjected to hydrolysis prior to analysis. With a daily dose of 2 mg of norethindrone, the mean plasma level of the metabolite was 24.8 ng/ml with a range of 22.8 ng/ml to 33.9 ng/ml.

Chromatography, High Pressure Liquid↗
PubMed1983

Substituted derivatives of A-nor-5 alpha-androstane and A-nor-5 alpha-estrane--structure and affinity for hormonal receptors.

The interactions of A-nor-5 alpha-androstane and A-nor-5 alpha-estrane derivatives with the estrogen and androgen receptors, have been evaluated by measuring their relative binding affinities (RBAs), under two sets of incubation conditions in order to discriminate between potent agonists from weak agonists with potential antagonist activities. Surprisingly some of these compounds which do not possess a phenolic hydroxyl group interact somewhat markedly with the estrogen receptor. This interaction is characteristic of weak estrogens, with potential anti-estrogenic activity (RBA values decreasing when increasing time and temperature of incubation). Results are in good agreement with data obtained in vivo. Moreover, some of these compounds interact also to some extent with the androgen receptor. Results will be discussed in order to outline some structure-activity relationships in these series.

Animals↗
PubMed1996

Heterocyclic steroids: synthesis of steroidal selena, tellura, and thialactones of estrane series.

A successful approach in the synthesis of 3 beta-acetoxy-17a-selena-D-homo-1,3,5(10)-estratrien-17 -one (5), 3 beta-acetoxy-17a tellura-D-homo-1,3,5(10)-estratrien-17-one (6), and 3 beta-acetoxy-17a-thia-D-homo-1,3,5(10)-estratrien-17-one (7) was achieved from 3 beta-acetoxy-1,3,5(10)-estratrien-17-one (1). The Baeyer-Villiger reaction of 3 beta-acetoxy-1,3,5(10)-estratrien-17-one (1) with perbenzoic acid afforded 3 beta-acetoxy-17a-oxa-D-homo-1,3,5(10)-estratrien-17-one (2), which on reaction with hydrobromic acid gave 3 beta-acetoxy-seco-13-bromo-1,3,5(10)-estratrien-16-oic acid (3). Treatment of bromo acid (3) with thionyl chloride gave 3 beta-acetoxy-seco-13-bromo-1,3,5(10)-estratrien-17 acid chloride (4), whose reaction with Se and Te in the presence of sodium borohydride gave the desired products 5 and 6. Reaction of 3 beta-acetoxy-seco-13-bromo-1,3,5(10)-estratrien-17 acid chloride (4) with sodium sulfide gave the thia lactone derivative (7).

Molecular Structure↗